Lake Street raised the firm’s price target on Profound Medical (PROF) to $12 from $11 and keeps a Buy rating on the shares. Profound raised gross proceeds of $36M via a registered direct offering and $6.45M in a private placement late last year and with “any capital concerns now behind the company,” investors can focus on Profound’s fundamental performance, the analyst argues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical’s TULSA-PRO Marks First Commercial Case at Johns Hopkins
- Profound Medical says Johns Hopkins treats first commercial TULSA-PRO case
- Profound Medical Raises US$6.45 Million in Canadian Private Placement
- Profound Medical Upsizes Private Placement to Raise US$6.45 Million
- Profound Medical Raises $36 Million in Equity Financing, Plans Additional Private Placement